Banco Sabadell promotes 'HealthTech' with the 9th edition of BStartup Health

Investment in Biotechnology

Banco Sabadell has launched the ninth edition of its BStartup Health program, aimed at early-stage healthcare startups with investments of up to €200.000. During Demo Day in Barcelona, ​​seven of its latest investments were presented, notably the ONIRIA THERAPEUTICS project to combat persistent cancer.


The program BStartup Health de Banco Sabadell has launched its ninth call for health startups in the early stages pre seed y seedoffering an investment of up to €200.000. The initiative was presented during a Demo Day at Barcelona, where the progress of seven investee companies was presented, with special attention to new cancer therapies.

The ninth edition of BStartup Health consolidates the commitment of Banco Sabadell through the healthcare innovation ecosystem, a strategic sector with high added value for the Spanish economy. The program targets early-stage projects developing disruptive solutions in the healthcare field, providing not only capital but also strategic support for their growth and consolidation in the global market.

ONIRIA THERAPEUTICS: Leading innovation in the fight against cancer

The main focus of the event was on ONIRIA THERAPEUTICSOne of the companies in which the company is involved is leading research against cancer persistence, one of the biggest challenges in oncology. During her presentation, a researcher from the company explained the progress in "modulating new targets to overcome cancer persistence," a line of research that promises to transform current treatments. This project underscores the importance of public-private collaboration, as it has the support of prestigious institutions such as the Universitat de Barcelona, ICREA, Mind the Gap and Asociación Española Contra el Cáncer.

The presentation was delivered to a qualified audience comprised of investors, scientists, and executives from the health and biotechnology ecosystem. The interest generated demonstrates the sector's potential. HealthTech Spanish to attract capital and position itself as a benchmark in international scientific research.

Concept Call for Proposals Details
Program 9th Edition BStartup Health
Organizing Entity Banco Sabadell
Addressed to Health sector startups
Maturity Phase Pre-seed and Seed
Maximum Investment 200.000 euros per project

Key points and frequently asked questions about BStartup Health

How does this initiative affect the Spanish innovation ecosystem?

The consolidation of programs like BStartup Health is fundamental for the Spanish ecosystem, as it injects smart capital at very early stages, where funding is most critical. Furthermore, it provides international visibility to the selected startups and attracts talent and foreign investment, strengthening Spain's position as a biotechnology and healthcare technology hub in Europe.

What opportunities does this represent for an early-stage healthcare technology company?

For a startup in the early stages pre seed o seedBeing selected by BStartup Health represents, beyond funding of up to €200.000, a key validation of your business model by a top-tier financial institution. Access to a network of investors, mentors, and potential strategic partners is an intangible asset that can significantly accelerate your market entry and internationalization process.

What should executives know about the investment potential in the HealthTech sector?

Managers and exporters should consider the sector HealthTech as a highly profitable area with great growth potential. The convergence of technology, biotechnology, and healthcare is generating solutions that address global challenges. Investing in or collaborating with startups in this sector not only offers business opportunities but also aligns companies with sustainability (ESG) trends and the development of a knowledge-based economy.

Coexia®

AI in the foreign trade

Hi! I'm Coexia. How can I help you today with your internationalization strategy?
Coexia AI of foreign trade